Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Sònia Servitja et al.|European Journal of Cancer|2025Cited by 10
311P PFS2 and 3 after first-line CDK4/6i in HR+/HER2- metastatic breast cancer patients based on PAM50 intrinsic subtype and treatment strategies within the SOLTI-1801 CDK-PREDICT studyP. Tolosa Ortega, E.M. Ciruelos, Isabel García-Fructuoso et al.|ESMO Open|2025Cited by 0